PM Barr

71 | FINAL ANALYSIS OF FIXED‐DURATION IBRUTINIB + VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) IN THE PHASE 2 CAPTIVATE STUDY

Paolo Ghia, PM Barr, John N. Allan, Tanya Siddiqi et autres

it, us, au, nz, es (code pays fourni par la source)

P671: TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL TREATED WITH TARGETED AGENTS IN REAL-WORLD SETTINGS

Anthony R. Mato, Bilal Manzoor, C. C. Coombs, Nicole Lamanna et autres

Background: Treatment (tx) options for patients (pts) with chronic/small lymphocytic leukemia (CLL/SLL) have expanded following regulatory approval of targeted agents. However, real-world evidence regarding pt outcomes and tx sequences is evolving. Aims: We assessed tx trends, sequences and outcomes following the introduction …

us, Afrique du Sud, de, ca, in, gb (code pays fourni par la source)

Factors impacting treatment selection in treatment-naive patients with CLL: a multicenter study

James B. Rhodes, Kavita Sail, Maryam Sarraf Yazdy, Borroughs R. Hill et autres

Predicting tumor lysis syndrome in venetoclax-treated CLL patients

Lindsey E. Roeker, Danielle M. Brander, Catherine C. Coombs, S. Schuster et autres

PF381 FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT‐NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY

Joanna Rhodes, Kavita Sail, Maryam Sarraf Yazdy, Brian T. Hill et autres

Background: The approval of novel targeted agents (TA) has revolutionized the treatment landscape for patients (pts) with chronic lymphocytic leukemia (CLL). Guidelines suggest that treatment selection between chemo‐immunotherapy (CIT) and TA is driven by several factors including age, disease stage, patient's fitness, …

us, Afrique du Sud, in, gb, de (code pays fourni par la source)

Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 Years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM))

Peter Hillmen, Alessandra Tedeschi, PM Barr, Tadeusz Robak et autres

Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM)

PM Barr, Thomas J. Kipps, Tadeusz Robak, Alessandra Tedeschi et autres

Improvement in quality of life and well-being in older patients with treatment-naive (TN) CLL : results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (resonate-2™)

Paolo Ghia, Alessandra Tedeschi, PM Barr, Tadeusz Robak et autres

International, randomized phase 3 study results: Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM))

JA Burger, Alessandra Tedeschi, PM Barr, Tadeusz Robak et autres